Trimel Pharmaceuticals Corp., of Toronto, reported first quarter 2015 revenues of $3.2 million from sales of Estrace (estradiol vaginal cream) in Canada, the sale of Natesto (testosterone nasal gel) inventory to support the U.S. product launch and revenues related to amortization of the $25 million up-front fee from the December 2014 licensing deal with Endo International plc, of Dublin, for exclusive marketing rights to Natesto in the U.S. and Mexico.